Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
August 31st, 2007
The Multiple Myeloma Research Consortium (MMRC) announced its participation in a Phase II study to determine the efficacy of LBH589 for the treatment of patients with relapsed or refractory multiple myeloma. LBH589 is an orally administered deacetylase inhibitor developed by Novartis Pharmaceuticals. The MMRC is the only research model of its kind bringing together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell. In addition to its most recent partnership with Novartis, the MMRC is facilitating several other clinical trials, including a Phase I study of NPI-...
Source: Drug Week (2007-08-31)
|
